Ozempic copies for $14 as the generic GLP-1 era starts in India [Los Angeles Times (CA)]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Los Angeles Times
Friday, crashing prices in the country with the third-largest overweight population. Natco Pharma Ltd. plans to make an injection for semaglutide — the active ingredient in both Ozempic and Wegovy — that will have a starting price of 1,290 rupees ($14) a month, on the first day the generics are allowed. The pen device is expected to launch by April and cost about 4,500 rupees a month, it said in a filing. By comparison, Novo's Wegovy pen starts at about 10,480 rupees ($113) in India and about $199 in the US under the self-pay model. Other companies are likely to price the starting dose between 3,000 rupees ($32) and 5,000 rupees a month, according to people familiar with the matter who did not want to be named as the information is competitive. While Canada was the first to lose patent protection for semaglutide in January, the Canadian health regulator hasn't approved any generics so far effectively making India the first major market to see a flood of copycat versions. The ens
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- India's Zydus, Lupin sign deal to co-market Semaglutide injections [Yahoo! Finance]Yahoo! Finance
- Strait of Hormuz standoff puts supply of America's generic drug prescriptions at risk [MSNBC.com]MSNBC.com
- India Semaglutide Patent Expiry Could Drive 50% Price Drop in Weight-Loss Drugs [Yahoo! Finance]Yahoo! Finance
- Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Ticagrelor Market Size to Reach USD 3.60 Billion by 2035, Fueled by Rising Cardiovascular Disease Burden and Growing Adoption of Advanced Antiplatelet Therapies – SNS Insider [Yahoo! Finance]Yahoo! Finance
RDY
Earnings
- 1/22/26 - Beat
RDY
Sec Filings
- 3/20/26 - Form 3
- 3/20/26 - Form 3
- 3/17/26 - Form 6-K
- RDY's page on the SEC website